Data Insights

Filter search results

By Company Name

No Filter Selected

By Disease Name

No Filter Selected

By Drug Name

No Filter Selected

By Themes

No Filter Selected

Showing 12 results out of 12

Company Profiles

Access comprehensive reports covering all the major players in the pharmaceutical industry

Gain a competitive edge
Enhance your sales strategy
Get forward-looking insights
Support your decision making

Buy Now

Data Insights

SI-101 by SIRPant Immunotherapeutics for Non-Hodgkin Lymphoma: Likelihood of Approval

SI-101 is under clinical development by SIRPant Immunotherapeutics and currently in Phase II for Non-Hodgkin Lymphoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - SI-101 in Non-Hodgkin Lymphoma

Data Insights

SI-101 by SIRPant Immunotherapeutics for Cutaneous T-Cell Lymphoma: Likelihood of Approval

SI-101 is under clinical development by SIRPant Immunotherapeutics and currently in Phase I for Cutaneous T-Cell Lymphoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - SI-101 in Cutaneous T-Cell Lymphoma

Data Insights

SI-101 by SIRPant Immunotherapeutics for Sezary Syndrome: Likelihood of Approval

SI-101 is under clinical development by SIRPant Immunotherapeutics and currently in Phase I for Sezary Syndrome. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - SI-101 in Sezary Syndrome

Data Insights

SI-101 by SIRPant Immunotherapeutics for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy: Likelihood of Approval

SI-101 is under clinical development by SIRPant Immunotherapeutics and currently in Phase I for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy. According...

Likelihood of Approval and Phase Transition Success Rate Model - SI-101 in Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy

Data Insights

SI-101 by SIRPant Immunotherapeutics for Mycosis Fungoides: Likelihood of Approval

SI-101 is under clinical development by SIRPant Immunotherapeutics and currently in Phase I for Mycosis Fungoides. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - SI-101 in Mycosis Fungoides

Data Insights

SI-101 by SIRPant Immunotherapeutics for Anaplastic Large Cell Lymphoma (ALCL): Likelihood of Approval

SI-101 is under clinical development by SIRPant Immunotherapeutics and currently in Phase I for Anaplastic Large Cell Lymphoma (ALCL). According...

Likelihood of Approval and Phase Transition Success Rate Model - SI-101 in Anaplastic Large Cell Lymphoma (ALCL)

Data Insights

SI-101 by SIRPant Immunotherapeutics for Relapsed Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

SI-101 is under clinical development by SIRPant Immunotherapeutics and currently in Phase I for Relapsed Chronic Lymphocytic Leukemia (CLL). According...

Likelihood of Approval and Phase Transition Success Rate Model - SI-101 in Relapsed Chronic Lymphocytic Leukemia (CLL)

Data Insights

SI-101 by SIRPant Immunotherapeutics for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

SI-101 is under clinical development by SIRPant Immunotherapeutics and currently in Phase I for Refractory Chronic Lymphocytic Leukemia (CLL). According...

Likelihood of Approval and Phase Transition Success Rate Model - SI-101 in Refractory Chronic Lymphocytic Leukemia (CLL)

Data Insights

SI-101 by SIRPant Immunotherapeutics for Nodal Marginal Zone B-Cell Lymphoma: Likelihood of Approval

SI-101 is under clinical development by SIRPant Immunotherapeutics and currently in Phase I for Nodal Marginal Zone B-Cell Lymphoma. According...

Likelihood of Approval and Phase Transition Success Rate Model - SI-101 in Nodal Marginal Zone B-Cell Lymphoma

Data Insights

SI-101 by SIRPant Immunotherapeutics for Diffuse Large B-Cell Lymphoma: Likelihood of Approval

SI-101 is under clinical development by SIRPant Immunotherapeutics and currently in Phase I for Diffuse Large B-Cell Lymphoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - SI-101 in Diffuse Large B-Cell Lymphoma

Data Insights

SI-101 by SIRPant Immunotherapeutics for Mantle Cell Lymphoma: Likelihood of Approval

SI-101 is under clinical development by SIRPant Immunotherapeutics and currently in Phase I for Mantle Cell Lymphoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - SI-101 in Mantle Cell Lymphoma

Data Insights

SI-101 by SIRPant Immunotherapeutics for Follicular Lymphoma: Likelihood of Approval

SI-101 is under clinical development by SIRPant Immunotherapeutics and currently in Phase I for Follicular Lymphoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - SI-101 in Follicular Lymphoma